CA19-9 radioimmunoassay regulatory update

The FDA granted marketing approval to Fujirebio's Fujirebio Diagnostics Inc. division (Malvern, Penn.) for its CA19-9 radioimmunoassay to monitor serum CA 19-9 levels in pancreatic cancer patients to ...